by barry101 | May 30, 2023 | Press Releases
– Company urges shareholders of record date, March 27, 2023, to vote your shares immediately if you have not already done so HOUSTON, May 30, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical...
by barry101 | May 11, 2023 | Press Releases
– Continued clinical and operational execution across ongoing development programs with growing body of positive preclinical and clinical data – Sufficient capital to fund operations into the third quarter of 2024 – Company to host conference call...
by barry101 | May 10, 2023 | Press Releases
– Actively recruiting in three Phase 1b/2 clinical trials (one of which is in Phase 2) – Recently completed first cohort in Phase 1b/2 trial evaluating Annamycin in combination with cytarabine (Ara-C) for the treatment of acute myeloid leukemia (AML);...
by barry101 | May 4, 2023 | Press Releases
HOUSTON, May 4, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | May 2, 2023 | Press Releases
Preliminary results demonstrate a durable complete response at starting dose level in elderly subject Positive results from first cohort allows Company to progress to second cohort in Phase 1b portion of the Phase 1b/2 trial with 230 mg/m2 dose of Annamycin HOUSTON,...
